197509-46-9

Usage

Molecular weight

628.75 g/mol

Piperidine ring

A six-membered nitrogen-containing ring that is commonly found in many pharmaceuticals and bioactive compounds.

Imidazole group

A five-membered nitrogen-containing ring that is often present in biologically active molecules.

Quinolylmethoxy group

A quinoline derivative with a methoxy substituent, which may contribute to the compound's biological activity.

Phenyl group

A six-membered carbon ring that is a common structural element in many organic compounds, including pharmaceuticals.

Methyl ester

An ester functional group derived from methanol, which may be involved in the compound's pharmacological properties.

Synthetic drug

The compound's complex structure and presence of biologically relevant groups suggest it may have potential as a synthetic drug.

Biochemical research

The compound's unique features may make it a useful tool in biochemical research, particularly in the study of receptor interactions or enzyme inhibition.

Pharmacology

The compound's potential pharmacological properties make it relevant to the study of drug action and drug development.

Biochemistry

The compound's structure and potential interactions with biological targets make it relevant to the study of biological processes at the molecular level.

Medicinal chemistry

The compound's potential therapeutic applications and unique structural features make it relevant to the design and development of new drugs.

Relevant academic research and scientific papers

Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents

This invention concerns the use of compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dotted line is an optional bond; n is 1 or 2; R1is hydrogen; halo; formyl; C1-4alkyl optionally substituted with hydroxy, C1-4alkyloxy, C1-4alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula —X—COOR5, —X—CONR6R7or —X—COR10wherein —X—is a direct bond, C1-4alkanediyl or C2-6alkenediyl; R5is hydrogen, C1-12alkyl, Ar, Het, C1-6alkyl substituted with C1-4alkyloxy, aryl or heteroaryl; R6and R7each independently are hydrogen or C1-4alkyl; R2is hydrogen, halo, C1-4alkyl, hydroxyC1-4alkyl, C1-4alkyloxycarbonyl, carboxyl, formyl or phenyl; R3is hydrogen, C1-4alkyl or C1-4alkyloxy; R4is hydrogen, halo, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl; Z is —CH2—, —CH2—CH2—, —CH═CH—, —CHOH—CH2—, —O—CH2—, 13 C(═O)—CH2—or —C(═NOH)—CH2—; —A—B—is a bivalent radical; A1is a direct bond, optionally substituted C1-6alkanediyl, C1-6alkanediyl-oxy-C1-6alkanediyl, carbonyl, C1-6alkanediylcarbonyl, optionally substituted C1-6alkanediyloxy; A2is a direct bond or C1-6alkanediyl; and Q is aryl; for the manufacture of a medicine for improving the bioavailability of a second pharmaceutical agent which is co-administered orally to a warm-blooded animal.

Fused imidazole derivatives as multidrug resistance modulators

This invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dotted line is an optional bond; n is1or2; R1is hydrogen; halo; formyl; C1-4alkyl optionally substituted with hydroxy, C1-4alkyloxy, C1-4alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula —X—COOR5, —X—CONR6R7or —X—COR10wherein —X— is a direct bond, C1-4alkanediyl or C2-6alkenediyl; R5is hydrogen, C1-12alkyl, Ar, Het, C1-6alkyl substituted with C1-4alkyloxy, aryl or heteroaryl; R6and R7each independently are hydrogen or C1-4alkyl; R2is hydrogen, halo, C1-4alkyl, hydroxyC1-4alkyl, C1-4alkyloxycarbonyl, carboxyl, formyl or phenyl; R3is hydrogen, C1-4alkyl or C1-4alkyloxy; R4is hydrogen, halo, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl; Z is —CH2—, —CH2—CH2—, —CH═CH—, —CHOH—CH2—, —O—CH2—, —C(═O)—CH2— or —C(═NOH)—CH2—; —A—B— is a bivalent radical; A1is a direct bond, optionally substituted C1-6alkanediyl, C1-6alkanediyl-oxy-C1-6alkanediyl, carbonyl, C1-6alkanediylcarbonyl, optionally substituted C1-6alkanediyloxy; A2is a direct bond or C1-6alkanediyl; and Q is aryl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for inhibiting or reversing the effects of multidrug resistance.